カテゴリ： GlobalData, アメリカ, 企業調査

Myriad Genetics Inc (MYGN)：企業の製品パイプライン分析2018

◆英語タイトル：Myriad Genetics Inc (MYGN) - Product Pipeline Analysis, 2018 Update
◆商品コード：DATA904C5277
◆発行会社（調査会社）：GlobalData
◆発行日：2018年9月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD1,500 ⇒換算￥222,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD2,250 ⇒換算￥333,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Myriad Genetics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Myriad Genetics Inc Company Overview 7
Myriad Genetics Inc Company Snapshot 7
Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview 7
Myriad Genetics Inc – Pipeline Analysis Overview 10
Business Description 10
Myriad Genetics Inc – Key Facts 10
Myriad Genetics Inc – Major Products and Services 11
Myriad Genetics Inc Pipeline Products by Development Stage 13
Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16
Myriad Genetics Inc Pipeline Products Overview 18
BRACAnalysis CDx – Talazoparib 18
BRACAnalysis CDx – Talazoparib Product Overview 18
ChemoPredict Test 19
ChemoPredict Test Product Overview 19
Diagnostic Assay – Lung Cancer 20
Diagnostic Assay – Lung Cancer Product Overview 20
Diagnostic Assay – HER2+/TNBC-Breast Cancer 21
Diagnostic Assay – HER2+/TNBC-Breast Cancer Product Overview 21
Diagnostic Assay – Juvenile Idiopathic Rheumatoid Arthritis 22
Diagnostic Assay – Juvenile Idiopathic Rheumatoid Arthritis Product Overview 22
Diagnostic Assay – Melanoma 23
Diagnostic Assay – Melanoma Product Overview 23
Diagnostic Assay – Prostate Cancer 24
Diagnostic Assay – Prostate Cancer Product Overview 24
Diagnostic Test – Alzheimer’s Disease 25
Diagnostic Test – Alzheimer’s Disease Product Overview 25
Diagnostic Test – Colon Cancer 26
Diagnostic Test – Colon Cancer Product Overview 26
Diagnostic Test – Kidney Damage 27
Diagnostic Test – Kidney Damage Product Overview 27
GeneSight Test – MDD 28
GeneSight Test – MDD Product Overview 28
GeneSight Test – MDD Clinical Trial 29
Genetic Risk Score Test 30
Genetic Risk Score Test Product Overview 30
Genetic Risk Score Test Clinical Trial 31
HRD Companion Diagnostic Test – Breast Cancer 32
HRD Companion Diagnostic Test – Breast Cancer Product Overview 32
Kidney Transplant Rejection Test 33
Kidney Transplant Rejection Test Product Overview 33
Multi-Biomarker Test – Ankylosing Spondylitis 34
Multi-Biomarker Test – Ankylosing Spondylitis Product Overview 34
Multi-Biomarker Test – Autoimmune Diseases 35
Multi-Biomarker Test – Autoimmune Diseases Product Overview 35
Multi-Biomarker Test – Inflammatory Diseases 36
Multi-Biomarker Test – Inflammatory Diseases Product Overview 36
Multi-Biomarker Test – Psoriatic Arthritis 37
Multi-Biomarker Test – Psoriatic Arthritis Product Overview 37
Multi-Biomarker Test – Systemic Lupus Erythematosus 38
Multi-Biomarker Test – Systemic Lupus Erythematosus Product Overview 38
myChoice Diabetes 39
myChoice Diabetes Product Overview 39
myChoice HRD (PARP) – Niraparib 40
myChoice HRD (PARP) – Niraparib Product Overview 40
myChoice HRD (PARP) – Niraparib Clinical Trial 41
myChoice HRD (PARP) – Talazoparib 43
myChoice HRD (PARP) – Talazoparib Product Overview 43
myChoice HRD (PARP) – Talazoparib Clinical Trial 44
myChoice HRD (Platinum) 45
myChoice HRD (Platinum) Product Overview 45
myChoice HRD (Platinum) Clinical Trial 46
myPath BiPolar 47
myPath BiPolar Product Overview 47
myPath Endometriosis 48
myPath Endometriosis Product Overview 48
myPath Pancreatic Cancer 49
myPath Pancreatic Cancer Product Overview 49
myPath Prostate Cancer 50
myPath Prostate Cancer Product Overview 50
myPath Psoriatic Arthritis 51
myPath Psoriatic Arthritis Product Overview 51
myPlan Renal Cancer 52
myPlan Renal Cancer Product Overview 52
myRisk Schizophrenia 53
myRisk Schizophrenia Product Overview 53
Prognostic Test – Bladder Cancer 54
Prognostic Test – Bladder Cancer Product Overview 54
SanoPredict 55
SanoPredict Product Overview 55
Tumor BRACAnalysis CDx – Veliparib 56
Tumor BRACAnalysis CDx – Veliparib Product Overview 56
VeriPsych Test – Bipolar Disorder 57
VeriPsych Test – Bipolar Disorder Product Overview 57
Myriad Genetics Inc – Key Competitors 58
Myriad Genetics Inc – Key Employees 59
Myriad Genetics Inc – Key Employee Biographies 60
Myriad Genetics Inc – Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Recent Developments 63
Myriad Genetics Inc, Recent Developments 63
Jul 18, 2018: Myriad announces coverage decision by Kroger Prescription Plans for Vectra DA 63
Jun 28, 2018: BRACAnalysis CDx Identifies Patients Who Respond to Lynparza in SOLO-1 Study 63
Jun 21, 2018: Top-Five National Payer Issues Positive Coverage Decision for Myriad’s Prolaris Test for Prostate Cancer 63
Jun 18, 2018: Myriad’s BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer 64
Jun 06, 2018: Crescendo Bioscience Announces Four Studies with Vectra DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting 64
Jun 01, 2018: Myriad Genetics Presents Second Pivotal Validation Study for riskScore Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 65
May 31, 2018: GeneSight Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting 66
May 23, 2018: Myriad Announces Seven New Payer Coverage Decisions for Prolaris 67
May 15, 2018: Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting 67
May 15, 2018: New Publication on Counsyl’s Foresight Carrier Screen Validates the Highly Accurate Detection of Couples At-Risk for Children With Serious Disease 69
Appendix 71
Methodology 71
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview 7
Myriad Genetics Inc Pipeline Products by Equipment Type 8
Myriad Genetics Inc Pipeline Products by Indication 9
Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 9
Myriad Genetics Inc, Key Facts 10
Myriad Genetics Inc, Major Products and Services 11
Myriad Genetics Inc Number of Pipeline Products by Development Stage 13
Myriad Genetics Inc Pipeline Products Summary by Development Stage 14
Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16
Myriad Genetics Inc Ongoing Clinical Trials Summary 17
BRACAnalysis CDx - Talazoparib - Product Status 18
BRACAnalysis CDx - Talazoparib - Product Description 18
ChemoPredict Test - Product Status 19
ChemoPredict Test - Product Description 19
Diagnostic Assay - Lung Cancer - Product Status 20
Diagnostic Assay - Lung Cancer - Product Description 20
Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Status 21
Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Description 21
Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Status 22
Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Description 22
Diagnostic Assay - Melanoma - Product Status 23
Diagnostic Assay - Melanoma - Product Description 23
Diagnostic Assay - Prostate Cancer - Product Status 24
Diagnostic Assay - Prostate Cancer - Product Description 24
Diagnostic Test - Alzheimer's Disease - Product Status 25
Diagnostic Test - Alzheimer's Disease - Product Description 25
Diagnostic Test - Colon Cancer - Product Status 26
Diagnostic Test - Colon Cancer - Product Description 26
Diagnostic Test - Kidney Damage - Product Status 27
Diagnostic Test - Kidney Damage - Product Description 27
GeneSight Test - MDD - Product Status 28
GeneSight Test - MDD - Product Description 28
GeneSight Test - MDD - PRIME Care (Precision Medicine In Mental Health Care) 29
Genetic Risk Score Test - Product Status 30
Genetic Risk Score Test - Product Description 30
Genetic Risk Score Test - Clinical Trial to Examine Use of Predictive Genetic Tests for Cancer Risks Assessment 31
HRD Companion Diagnostic Test - Breast Cancer - Product Status 32
HRD Companion Diagnostic Test - Breast Cancer - Product Description 32
Kidney Transplant Rejection Test - Product Status 33
Kidney Transplant Rejection Test - Product Description 33
Multi-Biomarker Test - Ankylosing Spondylitis - Product Status 34
Multi-Biomarker Test - Ankylosing Spondylitis - Product Description 34
Multi-Biomarker Test - Autoimmune Diseases - Product Status 35
Multi-Biomarker Test - Autoimmune Diseases - Product Description 35
Multi-Biomarker Test - Inflammatory Diseases - Product Status 36
Multi-Biomarker Test - Inflammatory Diseases - Product Description 36
Multi-Biomarker Test - Psoriatic Arthritis - Product Status 37
Multi-Biomarker Test - Psoriatic Arthritis - Product Description 37
Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Status 38
Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Description 38
myChoice Diabetes - Product Status 39
myChoice Diabetes - Product Description 39
myChoice HRD (PARP) - Niraparib - Product Status 40
myChoice HRD (PARP) - Niraparib - Product Description 40
myChoice HRD (PARP) - Niraparib - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy 41
myChoice HRD (PARP) - Niraparib - A Phase II, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens 41
myChoice HRD (PARP) - Niraparib - Phase I of Bevacizumab-Niraparib Combination. AVANOVA2 -A 3-arm, Phase II Randomized Study of Niraparib &/or Niraparib-bevacizumab Combination Against Bevacizumab Alone in HRD Platinum-sensitive Epithelial Ovarian Cancer: AVANOVA1 42
myChoice HRD (PARP) - Talazoparib - Product Status 43
myChoice HRD (PARP) - Talazoparib - Product Description 43
myChoice HRD (PARP) - Talazoparib - A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-type Patients with (i) Advanced Triple-negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-negative Breast Cancer or Other Solid Tumors with Either a Mutation in Homologous Recombination Pathway Genes 44
myChoice HRD (Platinum) - Product Status 45
myChoice HRD (Platinum) - Product Description 45
myChoice HRD (Platinum) - A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker 46
myPath BiPolar - Product Status 47
myPath BiPolar - Product Description 47
myPath Endometriosis - Product Status 48
myPath Endometriosis - Product Description 48
myPath Pancreatic Cancer - Product Status 49
myPath Pancreatic Cancer - Product Description 49
myPath Prostate Cancer - Product Status 50
myPath Prostate Cancer - Product Description 50
myPath Psoriatic Arthritis - Product Status 51
myPath Psoriatic Arthritis - Product Description 51
myPlan Renal Cancer - Product Status 52
myPlan Renal Cancer - Product Description 52
myRisk Schizophrenia - Product Status 53
myRisk Schizophrenia - Product Description 53
Prognostic Test - Bladder Cancer - Product Status 54
Prognostic Test - Bladder Cancer - Product Description 54
SanoPredict - Product Status 55
SanoPredict - Product Description 55
Tumor BRACAnalysis CDx - Veliparib - Product Status 56
Tumor BRACAnalysis CDx - Veliparib - Product Description 56
VeriPsych Test - Bipolar Disorder - Product Status 57
VeriPsych Test - Bipolar Disorder - Product Description 57
Myriad Genetics Inc, Key Employees 59
Myriad Genetics Inc, Key Employee Biographies 60
Myriad Genetics Inc, Subsidiaries 61
Glossary 73

List of Figures
Myriad Genetics Inc Pipeline Products by Equipment Type 8
Myriad Genetics Inc Pipeline Products by Development Stage 13
Myriad Genetics Inc Ongoing Clinical Trials by Trial Status 16

★海外企業調査レポート[Myriad Genetics Inc (MYGN)：企業の製品パイプライン分析2018]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Samsung C&T Corp：企業のM&A・事業提携・投資動向
    Samsung C&T Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Samsung C&T Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Nutricia GmbH：企業の戦略的SWOT分析
    Nutricia GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Arup Group Ltd：企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • The Emirates Group：企業の戦略・SWOT・財務情報
    The Emirates Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Biocurv Medical Instruments, Inc.：企業の戦略・SWOT・財務情報
    Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • OctreoPharm Sciences GmbH-医療機器分野：企業M&A・提携分析
    Summary OctreoPharm Sciences GmbH (OPS), a subsidiary of Ipsen SA is a clinical development biopharmaceutical company that develops radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company develops theranostic couple of antagonistic peptides for the diagnosis and treatme …
  • Generali Deutschland AG：企業の戦略・SWOT・財務情報
    Generali Deutschland AG - Strategy, SWOT and Corporate Finance Report Summary Generali Deutschland AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioLight Israeli Life Sciences Ltd (BOLT)-医療機器分野：企業M&A・提携分析
    Summary BioLight Israeli Life Sciences Ltd (Bio-Light), Bio Light Israeli Life Sciences Investments Ltd is an ophthalmic company that discovers, develops and commercializes products and product candidates for various ophthalmic conditions. The company invests in managing and commercializing biomedic …
  • Molex LLC：医療機器：M&Aディール及び事業提携情報
    Summary Molex LLC (Molex), a subsidiary of Koch Industries, is a US-based manufacturer of electronic components. The company principally focuses on manufacturing and sale of electronic, electrical and fiber optic interconnection systems. Molex's product portfolio includes switches, integrated produc …
  • Sun BioPharma Inc (SNBP)：企業の財務・戦略的SWOT分析
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • Cyan Limited：企業の戦略・SWOT・財務情報
    Cyan Limited - Strategy, SWOT and Corporate Finance Report Summary Cyan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cytogel Pharma LLC-製薬・医療分野：企業M&A・提携分析
    Summary Cytogel Pharma LLC (Cytogel Pharma) is a biopharmaceutical development company that provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offe …
  • Newpark Resources Inc (NR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Newpark Resources Inc (Newpark) offers fluid systems and services to oil and gas industry. The company offers drilling fluid products, solutions and services supporting directional, horizontal and deep water drilling projects. It grinds barite, which is used as a raw material in drilling flu …
  • Cincinnati Bell Inc (CBB)：企業の財務・戦略的SWOT分析
    Cincinnati Bell Inc (CBB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • GVK Power and Infrastructure Ltd (GVKPIL)：電力：M&Aディール及び事業提携情報
    Summary GVK Power and Infrastructure Ltd (GVKPIL), formerly Jegurupadu Operation & Maintenance Company Limited, is a diversified infrastructure company that operates across various sectors including energy, transportation, hospitality, resources, airports, and life sciences. It carries out construct …
  • Alitair Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Alitair Pharmaceuticals Inc (Alitair) is a pharmaceutical company that provides orphan drugs and medicine products. The company provides orphan drug products and RX and OTC cough and cold products. It offers orphan drug products such as ALT and oral drugs that are widely used to treat variou …
  • Syndax Pharmaceuticals Inc (SNDX)：企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Parkway Properties Inc：企業のM&A・事業提携・投資動向
    Parkway Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Parkway Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Oncolys BioPharma Inc (4588)-製薬・医療分野：企業M&A・提携分析
    Summary Oncolys BioPharma Inc (Oncolys) is a biotechnology company that discovers, and develops treatments for cancer and infectious diseases. The company imports and exports oncolytic viruses, drugs and medicines, and tumor diagnostic agents. Its pharmaceutical pipeline products include OBP-301, OB …
  • Companhia de Saneamento Basico do Estado de Sao Paulo (SBSP3)：企業の財務・戦略的SWOT分析
    Summary Companhia de Saneamento Basico do Estado de Sao Paulo (SABESP) is an environmental consulting company that is responsible for supplying water and collecting and treating sewage in municipalities of Sao Paulo state. The company provides water and sewage services in another four municipalities …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆